Each dot is one of the 48 Pharmaceuticals stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 12.6% and the median P/E 15.58. Pinned to the edge: 2 outliers on X and 3 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 45.5% | 46.74 | $1.36T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 42.83 | $688.76B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.7% | 50.48 | $521.69B | Pharmaceuticals |
| 4 | MRKMerck | 4.9% | 148.68OUT | $364.31B | Pharmaceuticals |
| 5 | AZNAstrazeneca | 7.8% | 25.92 | $285.96B | Pharmaceuticals |
| 6 | PFEPfizer | 1.3% | 40.85 | $164.73B | Pharmaceuticals |
| 7 | VRTXVertex Pharmaceuticals | 10.5% | 34.34 | $136.55B | Biotechnology |
| 8 | BMYBristol Myers Squibb | 4.2% | 14.02 | $129.66B | Pharmaceuticals |
| 9 | GSKGsk | 82.9% | 8.11 | $108.86B | Pharmaceuticals |
| 10 | SNYSanofi | -19.6% | 6.24 | $58.98B | Pharmaceuticals |
| 11 | TEVATeva Pharmaceutical Industries | 2.7% | 102.64 | $51.97B | Generic Drugs |
| 12 | ONCBeOne Medicines | 32.9% | 51.73 | $47.53B | Pharmaceuticals |
| 13 | GEHCGE HealthCare Technologies | 6.9% | 17.42 | $37.54B | Diagnostic Equipment |
| 14 | ALCAlcon | 8.0% | 54.90 | $36.13B | Medical Devices |
| 15 | UTHRUnited Therapeutics | 1.9% | 20.51 | $25.06B | Pharmaceuticals |
| 16 | NBIXNeurocrine Biosciences | 38.0% | 24.21 | $16.96B | Pharmaceuticals |
| 17 | EXELExelixis | 9.1% | 19.24 | $16.88B | Pharmaceuticals |
| 18 | BWXTBWX Technologies | 17.7% | 30.09 | $11.27B | Nuclear Equipment |
| 19 | CORTCorcept Therapeutics | 30.0% | 48.81 | $7.98B | Pharmaceuticals |
| 20 | AMRXAmneal Pharmaceuticals | 8.9% | 53.85 | $7.45B | Generic Drugs |
| 21 | FMSFresenius Medical Care AG | -49.1% | 6.71 | $6.16B | Healthcare Services |
| 22 | EWTXEdgewise Therapeutics | 36.6% | 4.95 | $5.03B | Pharmaceuticals |
| 23 | OGNOrganon | -3.2% | 17.14 | $3.65B | Pharmaceuticals |
| 24 | SUPNSupernus | 16.3% | 7.79 | $3.51B | Pharmaceuticals |
| 25 | TAKTakeda Pharmaceutical | -35.4% | 10.69 | $3.41B | Pharmaceuticals |
| 26 | ACADAcadia Pharmaceuticals | 14.8% | 8.93 | $3.24B | Pharmaceuticals |
| 27 | AUPHAurinia Pharmaceuticals | 21.0% | 6.68 | $2.11B | Pharmaceuticals |
| 28 | HRMYHarmony Biosciences Holdings | 19.8% | 11.04 | $1.98B | Pharmaceuticals |
| 29 | ETONEton Pharmaceuticals | 100.6% | 36.75 | $1.84B | Pharmaceuticals |
| 30 | ANIPAni Pharmaceuticals | 25.9% | 12.97 | $1.71B | Generic Drugs |
| 31 | NRIXNurix Therapeutics | 738.8%OUT | 5.86 | $1.69B | Biotechnology |
| 32 | JAZZJazz Pharmaceuticals | 13.5% | 7.59 | $1.55B | Pharmaceuticals |
| 33 | PCRXPacira BioSciences | 3.7% | 38.52 | $1.45B | Pharmaceuticals |
| 34 | INVAInnoviva | 12.8% | 7.09 | $1.36B | Pharmaceuticals |
| 35 | COLLCollegium Pharmaceutical | 7.7% | 21.05 | $786.73M | Pharmaceuticals |
| 36 | DCTHDelcath Systems | 38.1% | 111.41 | $714.55M | Medical Devices |
| 37 | ZVRAZevra Therapeutics | 75.2% | 6.91 | $539.71M | Pharmaceuticals |
| 38 | CRMDCorMedix | 92.5% | 5.90 | $370.36M | Pharmaceuticals |
| 39 | INCYIncyte | 24.9% | 0.61 | $246.78M | Pharmaceuticals |
| 40 | OMEROmeros | 1,532%OUT | 2.25 | $236.99M | Biotechnology |
| 41 | SIGASiga Technologies | -69.6% | 13.22 | $196.88M | Pharmaceuticals |
| 42 | CPIXCumberland Pharmaceuticals | 10.7% | 1.28 | $88.16M | Pharmaceuticals |
| 43 | VXRTVaxart | 22.3% | 3.01 | $87.73M | Biotechnology |
| 44 | FBIOFortress Biotech | 12.3% | 0.65 | $62.62M | Biotechnology |
| 45 | UGUnited Guardian | 23.6% | 12.43 | $38.87M | Pharmaceuticals |
| 46 | TXMDTherapeuticsMD | 33.9% | 177.40OUT | $21.64M | Pharmaceuticals |
| 47 | INNPFInnocan Pharma | -9.6% | 481.28OUT | $5.78M | Pharmaceuticals |
| 48 | PTIXProtagenic Therapeutics, Inc.new | -43.1% | 0.15 | $850.80K | Biotechnology |
Among Pharmaceuticals stocks, the largest companies growing revenue faster than the median (12.6%) while trading below the median P/E (15.58) are Gsk (GSK), Edgewise Therapeutics (EWTX), Supernus (SUPN), Acadia Pharmaceuticals (ACAD) and Aurinia Pharmaceuticals (AUPH). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Astrazeneca (AZN) and Pfizer (PFE).
The median P/E across the 48 Pharmaceuticals stocks plotted is 15.58, with the middle half between 6.86 and 41.34.
The median is 12.6%, with the middle half between 4.7% and 30.7%.
The rank correlation (Spearman) is -0.15, a weak negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 2 companies are outliers on Revenue Growth (1y) (TTM) and 3 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.